Atrium Therapeutics Launch: USD 270 Million Spinoff From Avidity Biosciences Targets Rare Cardiac Diseases With RNA Medicines

San Diego-based Atrium Therapeutics has debuted as a publicly traded company (Nasdaq: RNA) with approximately USD 270 million in cash and cash equivalents to advance RNA therapeutics for rare genetic cardiomyopathies. The Atrium Therapeutics launch follows the company's establishment as a spinoff created in connection with Novartis AG's acquisition of Avidity Biosciences. Rather than a traditional venture capital financing round, the company's initial capital base was structured through the corporate transaction that gave rise to the new entity, which now operates independently with two clinical-stage candidates, two undisclosed research-stage targets, and a proprietary platform for delivering small interfering RNA (siRNA) directly to cardiac tissue.

Investors and Use of Funds

Because Atrium Therapeutics emerged from the Novartis-Avidity transaction rather than a conventional Series A or later-stage round, the company did not disclose a lead investor or syndicate of participating venture firms in the manner typical of startup financing. The approximately USD 270 million in cash and cash equivalents represents the resources allocated to the new entity at the point of separation. The company said it plans to deploy the capital toward advancing its two lead development candidates through Investigational New Drug (IND)-enabling studies, Chemistry Manufacturing and Controls (CMC) manufacturing, and into clinical trials, while also continuing work on its undisclosed research-stage programs and next-generation delivery technology.

Atrium Therapeutics RNA Medicines: Pipeline Overview

Atrium's pipeline is anchored by two precision cardiology candidates, both targeting rare, autosomal dominant, progressive cardiomyopathies for which no approved therapies address the underlying genetic cause of disease.

ATR 1072 for PRKAG2 Syndrome

ATR 1072 is being developed as a potential PRKAG2 syndrome treatment. PRKAG2 syndrome is caused by mutations in the PRKAG2 gene, which encodes the Gamma 2 regulatory subunit of AMP-activated protein kinase (AMPK). These mutations enhance AMPK activity, leading to abnormal glycogen accumulation in heart muscle cells, which in turn causes thickened heart muscles, electrical conduction problems, and arrhythmias. The company estimates there are 1,000 to 2,000 people with PRKAG2 syndrome in the US. Current management is limited to symptomatic treatment.

IND-enabling studies and CMC manufacturing for ATR 1072 are underway, and the company said it expects to file an IND with the US FDA in the second half of 2026.

ATR 1086 for PLN Cardiomyopathy

ATR 1086 targets PLN (phospholamban) cardiomyopathy, a rare progressive cardiac disease caused by mutations in PLN, a regulator of the SERCA2a calcium pump. Pathogenic variants produce protein aggregates that disrupt endoplasmic reticulum processes and can lead to dilated, arrhythmogenic, or hypertrophic cardiomyopathies, with a significantly increased risk of heart failure and sudden cardiac death. The company estimates there are 2,000 to 4,000 people with pathogenic PLN variants in the US. CMC manufacturing is planned to support initiation of IND-enabling preclinical studies in 2026, with an IND submission targeting 2027. Pending supportive Phase 1 trial results, Atrium anticipates advancing PLN cardiomyopathy clinical trials alongside its PRKAG2 program.

Both programs are currently at the pre-IND stage, and no active registered clinical trials for ATR 1072 or ATR 1086 have been identified in public databases.

The Avidity Biosciences Spinoff and Platform Technology

Atrium Therapeutics' platform technology originates from Avidity Biosciences, which developed a proprietary approach combining the tissue selectivity of monoclonal antibodies and other targeted delivery ligands with the precision of oligonucleotide therapeutics. Avidity's core innovation, the Antibody-Oligonucleotide Conjugate (AOC) platform, links a monoclonal antibody targeting a tissue-specific cell-surface receptor to a therapeutic siRNA payload, enabling targeted, non-viral delivery of RNA therapeutics to extrahepatic tissues.

Avidity validated this approach in skeletal muscle, with clinical-stage programs in myotonic dystrophy type 1, facioscapulohumeral muscular dystrophy, and Duchenne muscular dystrophy, using a transferrin receptor 1 (TfR1)-targeting antibody as the delivery vehicle. The Avidity Biosciences spinoff that created Atrium effectively transferred the cardiac-focused applications of this conjugate technology to the new entity.

Atrium's adaptation of the platform for RNA therapeutics cardiomyopathy applications represents an extension of the AOC concept from skeletal muscle to cardiac muscle. The company's approach is designed to selectively target the underlying genetic drivers of cardiac disease through targeted, non-viral delivery of siRNA to cardiomyocytes. The specific receptor or ligand enabling cardiac tropism has not been publicly disclosed. The company said its approach builds upon learnings from delivery to skeletal muscle and applies them for delivery to the heart, overcoming challenges associated with non-specific tissue delivery.

This non-viral siRNA delivery approach carries potential advantages over adeno-associated virus (AAV)-based gene therapies for cardiac indications, including the possibility of repeat dosing without anti-capsid immune responses, titratable and reversible gene silencing, and chemical synthesis-based manufacturing. However, the platform remains at a preclinical stage for cardiac applications, and clinical validation in human cardiac tissue has not yet been demonstrated.

No information in the company's launch materials indicates that the foundational technology was licensed directly from a university or originated from an academic research laboratory. The broader scientific lineage of antibody-drug conjugate chemistry and RNA interference biology draws on decades of academic research, but Atrium's specific platform IP traces to Avidity's internal development work.

Leadership and Board

Atrium Therapeutics is led by Kathleen Gallagher as President and Chief Executive Officer. Sarah Boyce, who served as CEO of Avidity Biosciences prior to the Novartis acquisition, chairs Atrium's board of directors. Boyce described precision cardiology as an area where the team's experience in rare disease, drug development, and RNA therapeutics would be applied to advance the pipeline. No additional details regarding the broader management team's backgrounds, prior industry roles, or academic affiliations were provided in the company's launch disclosure.

Previous Funding and Partnerships

As a newly formed entity, Atrium Therapeutics has no history of prior funding rounds. The approximately USD 270 million in cash and cash equivalents represents the company's initial capitalization at launch. No licensing agreements, collaboration deals, or partnership arrangements beyond the foundational technology relationship with Avidity Biosciences have been publicly disclosed. The company's candidate naming convention — ATR 1072 and ATR 1086 — may reflect lineage to Avidity's internal pipeline numbering system, where muscle-targeted programs carried the "AOC" prefix with similar numeric identifiers, though this has not been formally confirmed.

Atrium trades on Nasdaq under the ticker RNA, the same symbol previously associated with Avidity Biosciences prior to the Novartis acquisition.

---

Spot something wrong? Report an issue with this article